24/7 Customer Support

+1 718 473 0872

U.S. Pharmaceutical Business Analysis

  • November 2011
  • 62 pages

Download This Report Now!

We value your privacy and will never rent or sell your email address.
Privacy Policy by TRUSTe

Refine your search results

Additional Related Reports

General Medicine And Specialty Medicine Market in the US

  • Researchers find Removal of Entire Lobe of Lung Offers Increased...
  • October 2014
    3 pages
  • Cancer  

  • United States  

View report >

General Medicine And Specialty Medicine Industry in the US

  • More Women Having Reconstruction Surgery after Breast Cancer Tre...
  • October 2014
    2 pages
  • Breast Cancer  

    Cancer  

  • United States  

View report >

Pathology Description in the US

  • Obesity Tied to Higher Cancer Risk for Crc Survivors
  • October 2014
    2 pages
  • Cancer  

    Obesity  

  • United States  

View report >

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women ...

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...


3 Companies

Company Profiles

CytRx Corp.

United States

Celgene Corp.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.